重性抑郁、双相障碍和精神分裂症多基因风险与丹麦人群抑郁风险的关系
结果显示,三种多基因风险评分均与抑郁风险升高相关,其中重性抑郁多基因风险关联最强;双相障碍多基因风险较高与抑郁发病年龄较早相关,但多基因风险对临床异质性影响较小。
要点
- 重性抑郁多基因风险每增加1个标准差,抑郁风险增加30%(HR 1.30,95%CI 1.27-1.33)。
- 双相障碍和精神分裂症多基因风险每增加1个标准差,抑郁风险分别增加5%和12%。
- 双相障碍多基因风险较高与抑郁发病年龄较早相关(β=-.07,SE=.02,P=.002)。
核心结论
- 重性抑郁多基因风险与普通人群首次抑郁发作相关,支持多基因评分反映抑郁的潜在遗传易感性。
- 双相障碍和精神分裂症多基因风险也与抑郁相关,提示这些疾病存在共同的遗传重叠。
- 多基因风险变异可能轻微影响临床表现的异质性,但关联似乎很小。
研究设计与样本
- 研究采用丹麦iPSYCH2012病例-队列研究,样本为1981年5月1日至2005年12月31日出生的人群代表样本。
- 使用修改的Cox回归估计抑郁风险,病例分析采用线性回归和多项回归。
- 暴露变量为基于精神病学基因组学联盟最新全基因组关联研究结果构建的重性抑郁、双相障碍和精神分裂症多基因风险评分。
主要发现
- 重性抑郁多基因风险每增加1个标准差,抑郁风险增加30%(HR 1.30;95%CI 1.27-1.33)。
- 双相障碍多基因风险每增加1个标准差,抑郁风险增加5%(HR 1.05;95%CI 1.02-1.07);精神分裂症多基因风险每增加1个标准差,抑郁风险增加12%(HR 1.12;95%CI 1.09-1.15)。
- 在抑郁病例中,双相障碍多基因风险较高与抑郁发病年龄较早相关(β=-.07;SE=.02;P=.002)。
关键数值与推荐
- 主要结局为首次抑郁发作(ICD-10编码F32),需在 hospital-based psychiatric care 接受治疗。
- 初始诊断严重程度采用ICD-10编码严重程度规格(轻度、中度、重度无精神病性症状、重度伴精神病性症状)及治疗设置(住院、门诊、急诊)衡量。
临床怎么用
- 重性抑郁多基因风险评分可用于评估普通人群的抑郁遗传易感性,但需结合临床和其他风险因素。
- 双相障碍和精神分裂症多基因风险也与抑郁风险相关,提示在抑郁患者中关注这些疾病的遗传重叠。
- 双相障碍多基因风险较高可能与抑郁发病年龄较早相关,但效应量较小,临床解读需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although the usefulness of polygenic risk scores as a measure of genetic liability for major depression (MD) has been established, their association with depression in the general population remains relatively unexplored. OBJECTIVE: To evaluate whether polygenic risk scores for MD, bipolar disorder (BD), and schizophrenia (SZ) are associated with depression in the general population and explore whether these polygenic liabilities are associated with heterogeneity in terms of age at onset and severity at the initial depression diagnosis. DESIGN, SETTING, AND PARTICIPANTS: Participants were drawn from the Danish iPSYCH2012 case-cohort study, a representative sample drawn from the population of Denmark born between May 1, 1981, and December 31, 2005. The hazard of depression was estimated using Cox regressions modified to accommodate the case-cohort design. Case-only analyses were conducted using linear and multinomial regressions. The data analysis was conducted from February 2017 to June 2018. EXPOSURES: Polygenic risk scores for MD, BD, and SZ trained using the most recent genome-wide association study results from the Psychiatric Genomics Consortium. MAIN OUTCOMES AND MEASURES: The main outcome was first depressive episode (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision [ICD-10] code F32) treated in hospital-based psychiatric care. Severity at the initial diagnosis was measured using the ICD-10 code severity specifications (mild, moderate, severe without psychosis, and severe with psychosis) and treatment setting (inpatient, outpatient, and emergency). RESULTS: Of 34 573 participants aged 10 to 31 years at censoring, 68% of those with depression were female compared with 48.9% of participants without depression. Each SD increase in polygenic liability for MD, BD, and SZ was associated with 30% (hazard ratio [HR], 1.30; 95% CI, 1.27-1.33), 5% (HR, 1.05; 95% CI, 1.02-1.07), and 12% (HR, 1.12; 95% CI, 1.09-1.15) increases in the hazard of depression, respectively. Among cases, a higher polygenic liability for BD was associated with earlier depression onset (β = -.07; SE = .02; P = .002). CONCLUSIONS AND RELEVANCE: Polygenic liability for MD is associated with first depression in the general population, which supports the idea that these scores tap into an underlying liability for developing the disorder. The fact that polygenic risk for BD and polygenic risk for SZ also were associated with depression is consistent with prior evidence that these disorders share some common genetic overlap. Variations in polygenic liability may contribute slightly to heterogeneity in clinical presentation, but these associations appear minimal.
引用
- Musliner KL, Mortensen PB, McGrath JJ, et al. Association of Polygenic Liabilities for Major Depression, Bipolar Disorder, and Schizophrenia With Risk for Depression in the Danish Population. JAMA Psychiatry. 2019. PMID: 30698613. doi:10.1001/jamapsychiatry.2018.4166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。